Black Diamond Therapeutics Inc (nasdaq:BDTX) Share Price

Company Profile

Business description
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
Contact
245 First Street
18th Floor
CambridgeMA02142
USA
T: +1 617 252-0848
https://www.blackdiamondtherapeutics.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
21

Recommended

Trading at an 18% discount, this wide-moat stock is a rare find.

Malik Ahmed Khan, CFA | 22 September 2026

Discounted exit raises investor concerns.

Yingqi Tan, CFA | 21 September 2026

The data and AI company is one of the world’s strongest private companies, but a PitchBook report says it’s unattractive at the current price.

Jacob Robbins | 21 September 2026

Index	Last price	Change	% Change
All Ordinaries	8,845.60	51.40	-0.58%
CAC 40	8,077.80	3.63	-0.04%
DAX 40	25,408.64	142.11	0.56%
Dow JONES (US)	51,768.43	418.45	0.81%
FTSE 100	10,695.25	15.26	0.14%
HKSE	24,510.09	251.04	-1.01%
NASDAQ	27,091.74	152.37	0.57%
Nikkei 225	66,364.20	850.21	1.30%
NZX 50 Index	13,811.11	13.72	-0.10%
S&P 500	7,742.38	38.25	0.50%
S&P/ASX 200	8,665.00	37.00	-0.43%
SSE Composite Index	3,888.37	48.15	-1.22%